Serebruany
Victor Serebruany, West Friendship, MD US
Patent application number | Description | Published |
---|---|---|
20100048654 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION - The invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of an ARB or its metabolite, especially Valsartan or its metabolite valeryl 4-hydroxy valsartan. Conditions to be treated by inhibition of platelet aggregation include acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion. | 02-25-2010 |
20110319349 | Methods for Reducing Platelet Activation and for the Treatment of Thrombotic Events - Methods and compositions for the treatment or prophylaxis of a disorder associated with platelet activation or enhanced thrombin activity are provided, that include the administration of an effective amount of a compound of the formula: | 12-29-2011 |
Victor L. Serebruany, West Friendship, MD US
Patent application number | Description | Published |
---|---|---|
20100056519 | COMPOSITION AND METHOD FOR REDUCING PLATELET ACTIVATION AND FOR THE TREATMENT OF THROMBOTIC EVENTS - A novel method of treating and preventing a vascular disease in an individual, comprising: selecting an individual having an elevated level of glycoprotein Ib, glycoprotein IIb/IIIa, PECAM-1, vitronectin receptor or thrombospondin receptor, or formation of platelet-neutrophil aggregates; and administering a therapeutically effective amount of a protease activated receptor-1 (PAR-1) antagonist, a pharmaceutical salt thereof, or a solvate thereof to the individual; and also, composition for treating cardiovascular diseases. | 03-04-2010 |
20110144049 | Treating Cardiac Arrhythmias, Heart Failure, Peripheral Artery Disease and Stroke with Cyclopentyl-Triazolo-Pyrimidine or Derivative Thereof - The present invention relates to new methods for treating and/or preventing cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering a composition comprising triazolopyrimidine, or derivative or metabolite thereof. In particular, the present invention relates to methods for treating cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering CycloPentyl-TriazoloPyrimidine. | 06-16-2011 |
20140162970 | Treating Cardiac Arrhythmias, Heart Failure, Peripheral Artery Disease and Stroke With Cyclopentyl-Triazolo-Pyrimidine or Derivative Thereof - The present invention relates to new methods for treating and/or preventing cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering a composition comprising triazolopyrimidine, or derivative or metabolite thereof. In particular, the present invention relates to methods for treating cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering CycloPentyl-TriazoloPyrimidine. | 06-12-2014 |
Victor L. Serebruany, Ellicott City, MD US
Patent application number | Description | Published |
---|---|---|
20090048173 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors - The invention relates to a method of treatment of resistance to platelet inhibitors, i.e. a method to overcome resistance of treatment with platelet inhibitors, said method comprising administering a therapeutically effective amount of dipyridamole in combination with a platelet inhibitor and, optionally, in combination with a third antithrombotic component such as direct thrombin inhibitors, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, heparin, low molecular weight heparin, argatroban, bivalrudin, hirulog or polyglycans to a patient in need thereof. The invention further relates to the use of dipyridamole for the manufacture of a pharmaceutical composition for treatment of resistance to platelet inhibitors. The invention also relates to a method to diagnose resistance to treatment with platelet inhibitors, said method comprising measurement of the density of binding of Annexin V on platelets. | 02-19-2009 |
20090192123 | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of Thrombin and/or by elevated expression of Thrombin receptors - A method of treatment of the human or non-human animal body for treating or preventing disorders caused by elevated thrombin or elevated thrombin receptor expression is disclosed, for example thromboembolic disease vascular syndromes, or proliferative diseases, which method comprises administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing dipyridamole, mopidamole or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions as well as the use of dipyridamole or mopidamole for the manufacture of these pharmaceutical compositions. | 07-30-2009 |
Victor L. Serebruany, Elicott City, MD US
Patent application number | Description | Published |
---|---|---|
20110160236 | Treating Vascular Events with Statins by Inhibiting PAR-1 and PAR-4 - The present invention relates to new methods for treating and/or preventing vascular events by inhibiting G-coupled Protease Activating Receptor (PAR)-1 and/or PAR-4 with the administration of statins. In one embodiment, individuals who are at risk for vascular events, but have cholesterol levels (e.g., total cholesterol or Low Density Lipoprotein) in normal ranges, are treated with statins. | 06-30-2011 |
Victor Leonid Serebruany, West Friendship, MD US
Patent application number | Description | Published |
---|---|---|
20080214599 | Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases - Use of a compound of formula (I) or a compound selected from the group consisting of a prasugrel metabolite, clopidogrel, a clopidogrel metabolite, ticlopidine, a ticlopidine metabolite, cangrelor, a cangrelor metabolite, AZD-6140, and an AZD-6140 metabolite for the treatment of and/or prevention of coagulation induced vascular diseases and recurrence thereof in a patient in need thereof. | 09-04-2008 |